The shares of Celgene Corporation (NASDAQ:CELG) has been pegged with a rating of Hold by Jefferies in its latest research note that was published on February 1st, 2019. The research company has also assigned a $95 price target. Jefferies wasn’t the only research firm that published a report of Celgene Corporation, with other equities research analysts also giving their opinion on the stock. Robert W. Baird advised investors in its research note published on January 4th, 2019, to Outperform the CELG stock. The stock had earned Neutral rating from Goldman when it published its report on January 4th, 2019. The stock was given Neutral rating by BTIG Research in its report released on December 21st, 2018. Cantor Fitzgerald was of a view that CELG is Overweight in its latest report on October 1st, 2018 while giving it a price target of $100. Standpoint Research thinks that CELG is worth Buy rating. This was contained in the firm’s report on June 18th, 2018.
Amongst the analysts that rated the stock, 0 have recommended investors to sell it, 12 believe it has the potential for further growth, thus rating it as Hold while 6 advised investors to purchase the stock. The consensus currently stands at a Hold while its average price target is $97.66. The price of the stock the last time has raised by 45.52% from its Week high price while it is raised higher than its 52-Week low price. A look at the stock’s other technical shows that its 14-day RSI now stands at 42.56.
The shares of the company added by 0.95% during the trading session on Monday, reaching a low of $84.58 while ending the day at $85.26. During the trading session, a total of 7.05 million shares were traded which represents a 38.09% incline from the average session volume which is 11.38M shares. CELG had ended its last session trading at 84.46. Celgene Corporation currently has a market cap of $60.78B, while its P/E ratio stands at 15.41, while its P/E earnings growth sits at 3.98, with a beta of 1.68. Celgene Corporation debt-to-equity ratio currently stands at 3.29, while its quick ratio hovers at 2.10. CELG 52-week low price stands at $58.59 while its 52-week high price is $95.30.
The company in its last quarterly report recorded $2.39 earnings per share which is above the $2.32 predicted by most analysts. The Celgene Corporation generated $4,037.00 million in revenue during the last quarter, which is slightly higher than the $3,988.21 million predicted by analysts. In the second quarter last year, the firm recorded $2.29 earnings per share. Compared to the same quarter last year, the firm’s revenue was up by 4.18%. Celgene Corporation has the potential to record 5.53 EPS for the current fiscal year, according to equities analysts.
Investment analysts at Societe Generale published a research note on January 24th, 2019 where it informed investors and clients that Viacom Inc. (NASDAQ:VIAB) is now rated as Hold. Robert W. Baird also rated VIAB as Upgrade on January 4th, 2019, with its price target of $54 suggesting that VIAB could surge by 16.34% from its current share price. Even though the stock has been trading at $28.86/share, analysts expect it to surge higher by 0.62% to reach $34.71/share. It started the day trading at $29.07 and traded between $28.41 and $29.04 throughout the trading session.
A look at its technical shows that VIAB’s 50-day SMA is 28.87 while its 200-day SMA stands at 29.83. The stock has a high of $34.44 for the year while the low is $23.31. The company’s P/E ratio currently sits at 8.21, while the P/B ratio is 1.53. The stock, however, witnessed a rise in its short on 2019-03-11. Compared to previous close which recorded 207,432 shorted shares, the short percent went up to 10.49 from 4.77, as 766,792 VIAB shares were shorted. At the moment, only of Viacom Inc. shares were sold short. The company’s average trading volume currently stands at 4.09M shares, which means that the short-interest ratio is just 4.30 days. Over the past seven days, the company moved, with its shift of -1.19%. Looking further, the stock has dropped -3.20% over the past 90 days while it lost -0.75% over the last six months.
The change in the stock’s fortunes has led to several institutional investors altering their holdings of the stock. The Vanguard Group Inc bought more VIAB shares, increasing its portfolio by +3.02% during the last quarter. This move now sees The Vanguard Group Inc purchasing 1,133,621 shares in the last quarter, thus it now holds 38,649,962 shares of VIAB, with a total valuation of $1,137,081,882. BlackRock Fund Advisors meanwhile bought more VIAB shares in the recently filed quarter, changing its stake to $574,383,753 worth of shares. Capital Research Management Co followed the path by decreasing its VIAB portfolio by -33.35% in the quarter. This means that Capital Research Management Co sold -8,592,239 shares in the last quarter and now controls 17,173,793 shares of the VIAB stock, with the valuation hitting $505,252,990.
Similarly, T Rowe Price Associates Inc increased its Viacom Inc. shares by +17.63% during the recently filed quarter. After buying 1,309,532 shares in the last quarter, the firm now controls 8,737,539 shares of Viacom Inc. which are valued at $257,058,397. In the same vein, AQR Capital Management LLC increased its Viacom Inc. shares by during the most recent reported quarter. The firm bought 595,987 shares during the quarter which increased its stakes to 7,604,114 shares and is now valued at $223,713,034. Following these latest developments, around 0.20% of Viacom Inc. stocks are owned by institutional investors and hedge funds.